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Presentation of Case
In April 2011, a 68-year-old man pre-
sented himself at our research clinic in rural
Tanzania with a three-month persistent
productive cough, chest pain, night sweats,
and recurrent nonmassive haemoptysis. He
denied fever, night sweats, weight loss, and
any recent contact with a known tuberculo-
sis case. A prior treatment with a broad-
spectrum antibiotic had not been successful.
The patient reported having been treated
for tuberculosis, diagnosed by sputum smear
ten years ago. On examination he was
afebrile, in a reduced general condition with
a body mass index of 17.1 kg/m2. Other
findings were bilateral reduced breath
sounds and mild clubbing. Testing for
HIV with two rapid tests (SD Bioline HIV
1/2 3.0 and Determine HIV-1/2) was
negative. Posteroanterior chest radiography
in an erect position showed a cavity of
60 mm673 mm diameter in the right upper
lobe containing an intracavitary focal mass
of 47 mm631 mm diameter with adjacent
moon-shaped radiolucency (Figure 1). A
second radiography in a supine position
showed a changed position of this focal mass
(Figure 2). A chest x-ray of the previous TB
episode was not available for comparison.
Smear microscopy of early morning and
spot sputum after Ziehl-Neelsen stain was
negative for acid-fast bacilli. A nucleic acid
amplification test (Xpert MTB/RIF) did not
detect Mycobacterium tuberculosis. Both the
early morning and spot sputum samples
were subsequently cultured on solid (Lo¨w-
enstein Jensen) and in liquid (MGIT) media,
neither of which showed mycobacterial
growth after eight and six weeks, respective-
ly. In order to isolate Aspergillus, a sabouraud
dextrose agar was inoculated directly with
sputum, but only Enterobacter cloacae could be
found. Due to lack of facilities, neither an
ELISA for IgG antibodies to Aspergillus nor
an Aspergillus precipitin test could be
performed.
Based on radiographies, a diagnosis of
single pulmonary aspergilloma was estab-
lished, but we could not exclude that the
symptoms were caused by tuberculosis
reactivation or reinfection. With negative
sputum smears, chest radiography findings
consistent with tuberculosis, and a lack of
response to a trial broad-spectrum antimi-
crobial agent, our patient fulfilled the
WHO criteria for sputum smear–negative
tuberculosis. Without options for surgical
treatment of pulmonary aspergilloma, we
were now faced with the decision of either
starting medication for pulmonary asper-
gilloma or sending the patient for tuber-
culosis treatment. Considering unavailabil-
ity of sputum culture results at this point
and our setting with high prevalence of
tuberculosis, we presented the case to the
National Tuberculosis and Leprosy Pro-
gram (NTLP) which initiated six-month
standard tuberculosis treatment according
to national guidelines, which implies
prescription of rifampin, isoniazid, etham-
butol, and pyrazinamide for two months,
followed by rifampin and isoniazid for four
months. After six months of antitubercu-
losis therapy, the patient was still in a
reduced condition, complaining about
productive cough and chest pain, but no
haemoptysis or night sweats. His body
mass index had increased to 19.2 kg/m2.
Radiographies, however, did not show any
improvement. Because of the persistent
symptomology, the patient was subse-
quently started on antifungal treatment
with itraconazole 200 mg daily for six
months. At the end of this period, the
treatment was extended for another six
months because the patient had reported
that the dispensary had not been able to
provide him with medication continuously
and therefore he had not been able to take
medication for the last three months of
treatment. At the last follow-up in October
2012 we noticed a clinical improvement of
the chest pain and no productive cough




Since the common term mycetoma applies
accurately to soft tissue infections, it is more
precise to use pulmonary aspergilloma to
describe an intracavitary fungal mycelial
growth in the lung. Pulmonary aspergilloma
caused by A. fumigatus is the most widespread
of the noninvasive forms of pulmonary
aspergillosis and develops in preexisting lung
cavities, most frequently tuberculous caverns
as seen in our case [1,2]. The aspergilloma
(fungus ball) consists of masses of fungal
mycelia, inflammatory cells, fibrin, mucus,
and tissue debris [3]. The diagnosis is usually
made clinically and radiographically without
lung biopsy. Mild haemoptysis is commonly
reported as the main symptom, but most
patients are asymptomatic. Bleeding is
usually caused by local invasion and endo-
toxic or mechanical irritation of exposed
bronchial blood vessels. Symptoms like
cough and dyspnoea are more likely related
to underlying diseases, making a clear
diagnosis difficult [1]. As with our patient,
50% of pulmonary aspergilloma sputum
cultures for Aspergillus spp. are negative [2].
Serum IgG antibodies to Aspergillus are
positive in most cases, but may be false
negative in patients under corticosteroid
therapy or in rare cases of pulmonary
aspergilloma caused by other species than
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A. fumigatus [1,3]. Chest radiographies show
intracavitary mass (fungus ball) with an air
crescent (Monod sign) in about two-thirds of
the cases [2,4]. This pattern is mostly
localized in the upper lobe and can change
position with gravity like in our radiogra-
phies. Computed tomography can be useful
to detect smaller lesions that may not be
apparent on conventional radiographies. An
increase of wall thickness of the preexisting
cavity suggests secondary infection [4]. Risk
factors for poor prognosis of pulmonary
aspergilloma include the severity of the
underlying lung disease, increase in size or
number of lesions, and immunosuppression
[1,3].
Treatment Difficulties
The first major decision is whether
therapy of the aspergilloma is required.
With 10% of asymptomatic cases resolving
spontaneously, treatment usually becomes
necessary only when the patient develops
symptoms [5]. Definitive treatment for an
aspergilloma is surgery of the affected lung,
which is indicated in case of recurrent or
severe haemoptysis. However, surgical
resection of the affected lung is associated
with considerable morbidity and mortality.
The mortality rates for surgical resection in
symptomatic patients vary between 4–8%,
the morbidity approaches 25% [6–8].
These rates can be explained partly because
Figure 1. Chest radiography showing a fungus ball with an air crescent in the right upper lobe.
doi:10.1371/journal.pntd.0002352.g001
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of the poor pulmonary function of many
patients with aspergilloma. Additionally, the
disease is rarely confined to the cavitary
lesion seen on chest radiography and the
adjacent lung and pleura are also involved
in the inflammatory response [7]. Lobecto-
my, segmentectomy, pneumonectomy, and
cavernostomy can be used as surgical
procedures. The risks of compromised
pulmonary function, bronchopleural fistula,
bleeding, and infection of the pleural space
may outweigh the benefits, depending on
the individual patient. In inoperable pa-
tients, primary treatment with antifungal
agents seems to be an option. To date, there
is no consistent evidence about the appro-
priate pharmacological treatment of single
pulmonary aspergilloma. The data guiding
the management of the disease are based on
uncontrolled trials and case reports [9].
Inhaled, intracavitary, and endobronchial
instillations of antifungal agents have shown
inconsistent success [1,10]. Among oral
antifungals, itraconazole seems to be most
effective due to its high tissue penetration,
but only small studies have shown benefit so
far. Because of its slow effect, treatment
regimens have to last at least six months.
The rates of symptomatic improvement
vary from 61% to 71%, and those of
radiological improvement from 14% to
23% [9–12]. However, due to the unpre-
dictable natural history of aspergilloma, it is
difficult to attribute clinical improvement to
a specific treatment. Parallel treatment with
standard tuberculosis medication should be
avoided, because of the well-documented
interaction between itraconazole and rifam-
pin which may lead to therapeutic failure
[13]. The role of newer antifungal azoles
such as voriconazole in the treatment of
aspergilloma has yet to be determined [1].
The Presenting Case
There is no epidemiological data on
pulmonary aspergilloma in Tanzania and
sub-Saharan Africa. However, the high
burden of tuberculosis in these countries
suggests a considerable number of unre-
ported cases. The case described here
should not illustrate a new treatment
approach but emphasize the limitations
and challenges in diagnosis and treatment
due to resource limitations, the tuberculosis
epidemic, and lack of consensus on thera-
peutic approach. The means used in this
case surpassed the resources of an average
rural setting, where we would have encoun-
tered even more limitations. Our initial
diagnosis was purely based on the typical
radiological findings illustrated in Figure 1
and Figure 2. Recurrent nonmassive hae-
moptysis and other clinical symptoms at the
Figure 2. Chest radiography in supine position showing a change of position of the fungus ball.
doi:10.1371/journal.pntd.0002352.g002
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first consultation were consistent with
pulmonary aspergilloma and other pulmo-
nary conditions, including tuberculosis.
Unfortunately, we could not compare
radiographies with the tuberculosis episode
that the patient had ten years before and
distinguish between new and old radiolog-
ical manifestations. Consequently, our case
fulfilled all criteria for a sputum smear–
negative case according to national stan-
dards [14] and the international standards
for tuberculosis care in high epidemic
countries [15], and the NTLP decided to
start treatment despite of the unavailability
of mycobacterial cultures at this point. If we
had attributed the symptoms purely to
pulmonary aspergilloma, surgical resection
would have been the best treatment choice.
Missing options of surgical treatment due to
lack of resources and epidemiological con-
cerns led to the decision to treat pharma-
cologically, first for tuberculosis and subse-
quently for pulmonary aspergilloma. With
total treatment duration of at least 12
months, it was difficult to guarantee proper
adherence to both treatments. In our case,
insufficient drug supply, as well as logistical
difficulties in making the antifungal drugs
available for the patient, led us to extend the
antifungal therapy for another six months.
It remains unclear if the treatment with
tuberculostatica, antifungal medication, or
the natural history of pulmonary aspergil-
loma caused the clinical improvement of the
patient, whose symptoms disappeared ex-
cept residual chest pain. Retrospectively,
although it was initially not possible to
exclude a smear-negative tuberculosis case,
treatment of pulmonary aspergilloma
should have been given priority while TB
treatment should have been started only in
the case of positive cultures.
The challenges in differential diagnosis
and therapy of pulmonary aspergilloma
demonstrated in this case underline the
necessity for incorporating management of
this frequently neglected TB-associated
disease into national TB treatment guide-
lines in endemic countries.
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Learning Points
N Pulmonary aspergilloma develops most frequently in residual tuberculous
cavities.
N Symptoms are often unspecific, making imaging the cornerstone of the
diagnosis.
N A mobile intracavitary mass with an air crescent are pathognomonic x-ray
findings.
N In symptomatic patients, surgical resection is the treatment of choice.
N Antifungal treatment can be considered as a therapeutic option, if surgery is
not possible.
N Parallel treatment with rifampin and itraconazole should be avoided because of
drug interactions.
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